drugset / Trial / NCT00484900

Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria

NCT00484900

Phase 3 Completed 1390 enrolled Dafra Pharma
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this open randomised multi-centre clinical trial is to test the hypothesis that three pills of the fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine, administered over 24 hours is not inferior in efficacy to the same drug administered over 48 hours and that the fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine As/SMP fdc, independently of the duration of its dose interval, is not inferior in efficacy to 6 - 24 pills (number of pills administered to respectively children and adults)of the 60 hours treatment of artemether/lumefantrine for the treatment of uncomplicated P. falciparum malaria.

Timeline

Start
2006-05
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Artemether Small molecule
Subject Artesunate Small molecule
Subject lumefantrine Small molecule
Subject pyrimethamine Small molecule
Subject sulphamethoxypyrazine Unknown